长链非编码VIM-AS1:放疗后乳腺纤维化易感性的生物标志物及转化生长因子β1驱动纤维化的促进因子
研究从COPERNIC collection回顾性选取放疗后发生或未发生重度乳腺纤维化的乳腺癌患者,对19株原代真皮成纤维细胞进行外显子组测序和RNA-seq转录组分析,识别出包含15个长链非编码RNA的乳腺纤维化易感性特征,其中VIM-AS1是与纤维化风险关联最强的生物标志物;功能实验显示敲低VIM-AS1可减少肌成纤维细胞活化、胶原基质产生和真皮类器官收缩,支持TGFB1/VIM-AS1/波形蛋白轴促纤维化作用。
要点
- 非编码转录组可区分放疗后纤维化与非纤维化状态,并识别出包含15个长链非编码RNA的乳腺纤维化易感性特征。
- VIM-AS1是与纤维化风险关联最强的长链非编码RNA生物标志物,此前未与任何纤维化疾病关联。
- 敲低VIM-AS1可减少肌成纤维细胞活化、胶原基质产生和真皮类器官收缩,提示其促纤维化作用。
核心结论
- 非编码RNA分析可提供与放疗后正常组织反应预测相关的特异性生物标志物,在RNA技术最新发展的框架下为下一代治疗方法开辟了前景。
研究设计与样本
- 从COPERNIC collection回顾性选取放疗后发生或未发生重度乳腺纤维化的乳腺癌患者,对从患者未照射皮肤分离的19株原代真皮成纤维细胞进行外显子组测序和RNA-seq转录组分析。
- 功能实验基于转化生长因子β1(TGFB1)诱导纤维化及在健康供者成纤维细胞中进行基因敲低。
主要发现
- 编码和非编码转录组可区分纤维化与非纤维化状态,并识别出包含15个长链非编码RNA的乳腺纤维化易感性特征。
- 风险比验证显示长链非编码RNA波形蛋白反义长链非编码RNA 1(VIM-AS1)是与纤维化风险关联最强的生物标志物。
- VIM-AS1在心脏纤维化和硬皮病数据集中上调,提示其在组织纤维化中可能具有普遍作用。
- 敲低VIM-AS1可减少肌成纤维细胞活化、胶原基质产生和真皮类器官收缩。
- VIM-AS1沉默后的RNA-seq数据分析指出其对复制、细胞周期和DNA修复的调控,且VIM-AS1与波形蛋白基因共调控,支持TGFB1/VIM-AS1/波形蛋白轴的促纤维化功能,靶向成纤维细胞-肌成纤维细胞转化的动态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fibrosis is a common late complication of radiation therapy. Molecular dysregulations leading to fibrosis have been characterized for the coding part of the genome, notably those involving the TGFB1 gene network. However, because a large part of the human genome encodes RNA transcripts that are not translated into proteins, exploring the involvement of the noncoding part of the genome in fibrosis susceptibility and development was the aim of this work. METHODS AND MATERIALS: Breast cancer patients having or not having developed severe breast fibrosis after radiation therapy were retrospectively selected from the COPERNIC collection. Exome sequencing and RNA-seq transcriptomic profiling were performed on 19 primary dermal fibroblast strains isolated from the patients' nonirradiated skin. Functional experiments were based on fibrogenic induction by transforming growth factor-Beta1 (TGFB1) and gene knockdown in healthy donor fibroblasts. RESULTS: Coding and noncoding transcriptomes discriminated fibrosis from nonfibrosis conditions, and a signature of breast fibrosis susceptibility comprising 15 long noncoding RNAs (lncRNAs) was identified. A hazard ratio validation showed that the lncRNA vimentin antisense long noncoding RNA 1 (VIM-AS1) was the best biomarker associated with fibrosis risk. This lncRNA has not been previously associated with any fibrotic disorder, but we found it upregulated in data sets from cardiac fibrosis and scleroderma, suggesting a general role in tissue fibrosis. Functional experiments demonstrated a profibrotic action of VIM-AS1 because its knockdown reduced myofibroblast activation, collagen matrix production, and dermal organoid contraction. RNA-seq data analysis after VIM-AS1 silencing also pointed out the regulation of replication, cell cycle, and DNA repair. Mechanistically, because VIM-AS1 was found coregulated with the vimentin gene, these data support a profibrotic function of the TGFB1/VIM-AS1/vimentin axis, targeting the dynamics of fibroblast-myofibroblast transition. CONCLUSIONS: Noncoding RNA analysis can provide specific biomarkers relevant to the prediction of normal tissue responses after radiation therapy, which opens perspectives of next-generation approaches for treatment, in the frame of the recent developments of RNA-based technologies.
引用
- Vinasco-Sandoval T, Moratille S, Crechet F, et al. Long Noncoding VIM-AS1: Biomarker of Breast Fibrosis Susceptibility After Radiation Therapy and Promoter of Transforming Growth Factor Beta1-Driven Fibrosis. Int J Radiat Oncol Biol Phys. 2024. PMID: 39436333. doi:10.1016/j.ijrobp.2024.09.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。